996 resultados para HLA-DR
Resumo:
Variation in the 3' untranslated region (3'UTR) of the HLA-C locus determines binding of the microRNA Hsa-miR-148a, resulting in lower cell surface expression of alleles that bind miR-148a relative to those alleles that escape its binding. The HLA-C 3'UTR variant was shown to associate with HIV control, but like the vast majority of disease associations in a region dense with causal candidates, a direct effect of HLA-C expression level on HIV control was not proven. We demonstrate that a MIR148A insertion/deletion polymorphism associates with its own expression levels, affecting the extent to which HLA-C is down-regulated, the level of HIV control, and the risk of Crohn disease only among those carrying an intact miR-148a binding site in the HLA-C 3'UTR. These data illustrate a direct effect of HLA-C expression level on HIV control that cannot be attributed to other HLA loci in linkage disequilibrium with HLA-C and highlight the rich complexity of genetic interactions in human disease.
Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.
Resumo:
OBJECTIVES We aimed to investigate potential associations between human leukocyte antigen (HLA) class I and class II alleles and the development of anaphylactic/anaphylactoid reactions in patients with multiple sclerosis (MS) treated with natalizumab. METHODS HLA class I and II genotyping was performed in patients with MS who experienced anaphylactic/anaphylactoid reactions and in patients who did not develop infusion-related allergic reactions following natalizumab administration. RESULTS A total of 119 patients with MS from 3 different cohorts were included in the study: 54 with natalizumab-related anaphylactic/anaphylactoid reactions and 65 without allergic reactions. HLA-DRB1*13 and HLA-DRB1*14 alleles were significantly increased in patients who developed anaphylactic/anaphylactoid reactions (p M-H = 3 × 10(-7); odds ratio [OR]M-H = 8.96, 95% confidence interval [CI] = 3.40-23.64), with a positive predictive value (PPV) of 82%. In contrast, the HLA-DRB1*15 allele was significantly more represented in patients who did not develop anaphylactic/anaphylactoid reactions to natalizumab (p M-H = 6 × 10(-4); ORM-H = 0.2, 95% CI = 0.08-0.50), with a PPV of 81%. CONCLUSIONS HLA-DRB1 genotyping before natalizumab treatment may help neurologists to identify patients with MS at risk for developing serious systemic hypersensitivity reactions associated with natalizumab administration.
Resumo:
The Journal of Medicine and Philosophy has been impoverished by the loss of Dr. Francesc Abel Fabre, S.J. (1933–2011), one of the founders of bioethics and a long-time member of the Editorial Advisory Board. 2011 brought the death of Dr. Francesc Abel Fabre, S.J., at the age of 78. He was the pioneer of European bioethics. Dr. Abel learned the discipline at Georgetown University, working side by side with the founder and first director of the Kennedy Institute of Ethics, André Hellegers, as bioethics itself was coming into existence. He went from this experience to establish the Institute Borja of Bioethics in Catalonia in 1976, the first center of bioethics in Spain and in Europe. Through his scholarship and teaching, he established an influential dialogue in bioethics, as well as ethics committees in hospitals and in research centers. In 1986 he joined in founding the European Association of Centres of Medical Ethics, an organization in which he was involved and participated for the last 25 years. He contributed crucially to bioethics across the world, especially through the International Study Group on Bioethics (1980–1994). He was widely recognized as an outstanding bioethics expert in Latin America.
Resumo:
Comprend : Corps gras, huiles végétales et animales, suifs, cires
Resumo:
Collection : Science et religion ; 65
